Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Cellectis Nom. Stock

Price
 
€16.35
-0.18
-1.090%
Target price
-
17.01.20 / Frankfurt WKN: A0MKPR / Name: Cellectis / Stock / Biotechnologie & medizinische Forschung
Latest predictions
-
17.12.19
buy
Your prediction

Cellectis Nom. Stock

We can see a decrease in the price for Cellectis Nom.. Compared to yesterday it has lost -€0.180 (-1.090%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Cellectis Nom. stock is not clear.
Register To Post

Other discussions about Cellectis Nom. Stock

New thread

News

First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia


Regulatory News:



Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on

Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery


Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth:ALCLS; Nasdaq:CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene-edited

1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia


Regulatory News:



Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on

Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells


Regulatory News:



Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today

Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications


Regulatory News:



Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019


Regulatory News:



Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic